Drug Profile


Alternative Names: CR-2249; Nebostinel; XY 2401

Latest Information Update: 08 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rottapharm
  • Developer Rottapharm; Rottapharm Madaus; Xytis
  • Class Neuroprotectants; Nootropics; Pentanoic acids; Small molecules
  • Mechanism of Action Glycine NMDA-associated agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cocaine abuse; Schizophrenia
  • Discontinued Alzheimer's disease; Major depressive disorder

Most Recent Events

  • 08 Jun 2015 Phase-II development for schizophrenia (negative, cognitive and mood symptoms) and drug abuse (cocaine abuse) is ongoing in Italy and USA, respectively
  • 08 Nov 2014 Phase-II development is ongoing in the US and Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top